Kyntra Bio (MEX:KYNB) Other Current Liabilities: MXN47.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KYNB Kyntra Bio Inc MEX:KYNB
35 GF Score
Price MXN127.90
GF Value MXN98.73
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Other Current Liabilities?

Kyntra Bio MEX:KYNB 35 Other Current Liabilities is MXN47.8 Mil as of Mar. 2026. GuruFocus rates MEX:KYNB with a GF Score™ of 35/100 and a GF Value™ of MXN98.73 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Kyntra Bio's other current liabilities for the quarter that ended in Mar. 2026 was MXN47.8 Mil.

Kyntra Bio's quarterly other current liabilities declined from Sep. 2025 (MXN67.5 Mil) to Dec. 2025 (MXN56.8 Mil) and declined from Dec. 2025 (MXN56.8 Mil) to Mar. 2026 (MXN47.8 Mil).

Kyntra Bio's annual other current liabilities increased from Dec. 2023 (MXN1,382.3 Mil) to Dec. 2024 (MXN1,466.0 Mil) but then declined from Dec. 2024 (MXN1,466.0 Mil) to Dec. 2025 (MXN56.8 Mil).

Kyntra Bio Other Current Liabilities Related Terms

Kyntra Bio Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Other Current Liabilities Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.64 141.31 1,382.28 1,466.01 56.81

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 256.67 245.19 67.45 56.81 47.80
MEX:KYNB
35GF Score
Kyntra Bio Inc MEX:KYNB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN47.8 Mil mean?
Kyntra Bio (MEX:KYNB) has a Other Current Liabilities of MXN47.8 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kyntra Bio.
Is Kyntra Bio's Other Current Liabilities too high?
Kyntra Bio's current Other Current Liabilities is MXN47.8 Mil. Overall, Kyntra Bio has a GF Score™ of 35/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Other Current Liabilities compare to TVGN and PSTV?
Kyntra Bio's Other Current Liabilities of MXN47.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kyntra Bio. Kyntra Bio's current Other Current Liabilities is MXN47.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (MEX:KYNB) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN98.73, compared to a current price of MXN127.90 — trading 29.5% above its estimated fair value. The current Other Current Liabilities is MXN47.8 Mil. Kyntra Bio's overall GF Score™ is 35/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Kyntra Bio (MEX:KYNB), the current Other Current Liabilities is MXN47.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (MEX:KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of MXN127.90 is trading 29.5% above its estimated GF Value™ of MXN98.73. GuruFocus considers Kyntra Bio to be Modestly Overvalued.

Key valuation signals for MEX:KYNB:

  • Other Current Liabilities: MXN47.8 Mil
  • GF Value™: MXN98.73 vs. price of MXN127.90 (29.5% above fair value)
  • GF Score™: 35/100 with 8 warning signs

No single metric tells the full story. See the MEX:KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Other Exchanges KYNB:USA0IL8:UK1FG0:Germany
Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
35GF Score

Get the complete analysis for MEX:KYNB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN127.90
Price
MXN98.73
GF Value